TY - JOUR
T1 - Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
AU - Thomas, Deborah A.
AU - Cortes, Jorge
AU - O'Brien, Susan
AU - Pierce, Sherry
AU - Faderl, Stefan
AU - Albitar, Maher
AU - Hagemeister, Frederick B.
AU - Cabanillas, Fernando F.
AU - Murphy, Sharon
AU - Keating, Michael J.
AU - Kantarjian, Hagop
PY - 1999/8
Y1 - 1999/8
N2 - Purpose: To evaluate response and outcome with a front-line intensive multiagent chemotherapy regimen in adults with Burkitt's-type acute lymphoblastic leukemia (B-ALL). Patients and Methods: From September 1992 to June 1997, 26 consecutive adults with newly diagnosed untreated B-ALL received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD). Their median age was 58 years (range, 17 to 79 years), and 46% were ± 60 years. Patients received Hyper-CVAD alternated with courses of high-dose methotrexate and cytarabine. Granulocyte colony- stimulating factor and prophylactic antibiotics were administered for all eight planned courses. CNS prophylaxis alternated intrathecal methotrexate and cytarabine on days 2 and 7 of each course. Results: Complete remission (CR) was obtained in 21 patients (81%). There were five induction deaths (19%). The median time to CR was 22 days (range, 15 to 89 days); 70% achieved CR within 4 weeks. The 3-year survival rate was 49% (± 11%); the 3-year continuous CR rate was 61% (± 11%). Twelve CR patients (57%) were in continuous CR at a median follow-up of 3+ years (range, 13+ months to 6.5+ years). Characteristics predicting for worse survival were age ≥ 60 years, poor performance status, anemia, thrombocytopenia, peripheral blasts, and increased lactate dehydrogenase level. The 3-year survival rate was 77% for 14 patients younger than 60 years and 17% for 12 patients ≥ 60 years (P < .01). Regression analysis identified older age, anemia, and presence of peripheral blasts as independent factors associated with shorter survival. Patients could be stratified according to (1) no or one adverse feature, (2) two adverse features, and (3) all adverse features. The 3-year survival rates were 89%, 47%, and 0%, respectively (P < .01). Conclusion: Hyper-CVAD is effective in adult B-ALL. Identification of patients with high risk for relapse and improved methods to detect residual disease may result in risk- oriented approaches.
AB - Purpose: To evaluate response and outcome with a front-line intensive multiagent chemotherapy regimen in adults with Burkitt's-type acute lymphoblastic leukemia (B-ALL). Patients and Methods: From September 1992 to June 1997, 26 consecutive adults with newly diagnosed untreated B-ALL received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD). Their median age was 58 years (range, 17 to 79 years), and 46% were ± 60 years. Patients received Hyper-CVAD alternated with courses of high-dose methotrexate and cytarabine. Granulocyte colony- stimulating factor and prophylactic antibiotics were administered for all eight planned courses. CNS prophylaxis alternated intrathecal methotrexate and cytarabine on days 2 and 7 of each course. Results: Complete remission (CR) was obtained in 21 patients (81%). There were five induction deaths (19%). The median time to CR was 22 days (range, 15 to 89 days); 70% achieved CR within 4 weeks. The 3-year survival rate was 49% (± 11%); the 3-year continuous CR rate was 61% (± 11%). Twelve CR patients (57%) were in continuous CR at a median follow-up of 3+ years (range, 13+ months to 6.5+ years). Characteristics predicting for worse survival were age ≥ 60 years, poor performance status, anemia, thrombocytopenia, peripheral blasts, and increased lactate dehydrogenase level. The 3-year survival rate was 77% for 14 patients younger than 60 years and 17% for 12 patients ≥ 60 years (P < .01). Regression analysis identified older age, anemia, and presence of peripheral blasts as independent factors associated with shorter survival. Patients could be stratified according to (1) no or one adverse feature, (2) two adverse features, and (3) all adverse features. The 3-year survival rates were 89%, 47%, and 0%, respectively (P < .01). Conclusion: Hyper-CVAD is effective in adult B-ALL. Identification of patients with high risk for relapse and improved methods to detect residual disease may result in risk- oriented approaches.
UR - http://www.scopus.com/inward/record.url?scp=0032812621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032812621&partnerID=8YFLogxK
U2 - 10.1200/jco.1999.17.8.2461
DO - 10.1200/jco.1999.17.8.2461
M3 - Article
C2 - 10561310
AN - SCOPUS:0032812621
SN - 0732-183X
VL - 17
SP - 2461
EP - 2470
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 8
ER -